FILTER
FILTERED INTERVIEW RESULTS
Juan Alfaro
GENERAL MANAGER, INGENALSE
Ingenalse is a small Chilean engineering company that works with some of Chile’s largest miners.
Juan Castaño
CEO, AMPHOS 21 CHILE
Amphos 21 helps Chile’s miners to cope with the dearth of water in a sustainable and efficient manner.
Tomás Buttazzoni
GENERAL MANAGER, TECHNOSTEEL
Technosteel is a Chilean company developing solutions for conveyor belts and equipment for mining exploration.
Joaquín Villarino
PRESIDENT, CONSEJO MINERO
Consejo Minero explains the issues that are currently preoccupying Chile’s miners.
Eduardo Nilo
GENERAL MANAGER, METSO CHILE
Metso speaks to GBR about its intentions for the Chilean market.
Octavio Araneda
CEO, CODELCO
Codelco CEO explains his strategic transformation plan that aims to ensure continued and profitable operations for the Chilean giant over the next decade.
Joel Araujo Strul
CEO, AMERICAN AIR
American Air specializes in light vehicle, medium duty and heavy truck air conditioning systems and was one of the first air conditioning companies to supply the mining industry in Chile.
Angello Passalacqua
BUSINESS MANAGER, DYNO NOBEL
Dyno Nobel explains how it is expanding its presence in the Chilean market by introducing new services and products.
Dale Clayton
MANAGING DIRECTOR – CHILE, LIEBHERR
Leibherr speaks to GBR about its offering to the mining industry in Chile.
Aaron Puna
CEO, ANGLO AMERICAN CHILE
Anglo American Chile explains how its new approach to sustainable mining is adapted to its developments in Chile.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
